Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 4/2012

01.12.2012 | short review

Appraisal of recent knowledge in primary central nervous system lymphoma

verfasst von: Emerenziana Marturano, MD, Andrés J. M. Ferreri, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare and aggressive brain tumor with an unsatisfactory prognosis. This is probably caused by the little knowledge of the biology and the molecular mechanisms of the disease with a consequent lacking of new targeted therapies and by the poor clinical conditions and performance status of patients, rendering their enrollment in prospective trials very difficult. Chemotherapy followed by radiotherapy is the most commonly used strategy for patients with PCNSL, which is not only associated with better efficacy rates, but also with high incidence of severe neurotoxicity. A relevant dilemma in PCNSL treatment regards the choice between strategies designed to intensify therapy to improve the cure rate, versus strategies of treatment deescalation to avoid severe neurotoxicity. The efficacy of chemotherapy is strongly limited by the special functional and microenvironmental characteristics of the central nervous system (CNS), which is variably protected by the blood–brain barrier (BBB) and includes extensive chemotherapy sanctuaries where tumor cells grow undisturbed. Methotrexate plus cytarabine combination is the current standard chemotherapeutic approach for newly diagnosed PCNSL, since it is supported by a recently published randomized trial. Other strategies are based on the use of other chemotherapy agents (temozolomide, topotecan, and thiotepa) and monoclonal antibodies (rituximab). Consolidation after chemotherapy represents the best role for radiotherapy. Some authorities are investigating in randomized trials which impact on outcome and neurotolerability of replacing consolidation radiotherapy with other strategies such as high-dose chemotherapy (HDC) supported by autologous stem cell transplantation (ASCT).
Literatur
1.
Zurück zum Zitat Rubenstein J, Ferreri AJ, Pittaluga S. Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma. 2008;49(Suppl 1):43–51.PubMedCrossRef Rubenstein J, Ferreri AJ, Pittaluga S. Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma. 2008;49(Suppl 1):43–51.PubMedCrossRef
2.
Zurück zum Zitat Ferreri AJ, Abrey LE, Blay JY, et al. Summary statement on primary central nervous system lymphomas from the eighth international conference on malignant lymphoma, Lugano, Switzerland, June 12–15, 2002. J Clin Oncol. 2003;21(12):407–14.CrossRef Ferreri AJ, Abrey LE, Blay JY, et al. Summary statement on primary central nervous system lymphomas from the eighth international conference on malignant lymphoma, Lugano, Switzerland, June 12–15, 2002. J Clin Oncol. 2003;21(12):407–14.CrossRef
4.
Zurück zum Zitat Lippens RJ, Winograd B. Methotrexate concentration levels in the cerebrospinal fluid during high-dose methotrexate infusions: an unreliable prediction. Pediatr Hematol Oncol. 1988;5(2):115–24.PubMedCrossRef Lippens RJ, Winograd B. Methotrexate concentration levels in the cerebrospinal fluid during high-dose methotrexate infusions: an unreliable prediction. Pediatr Hematol Oncol. 1988;5(2):115–24.PubMedCrossRef
5.
Zurück zum Zitat Ferreri AJ, Guerra E, Regazzi M, et al. Area under the curve of methotrexate and creatinine clearance are outcome determining factors in primary CNS lymphomas. Br J Cancer. 2004;90(2):353–8.PubMedCrossRef Ferreri AJ, Guerra E, Regazzi M, et al. Area under the curve of methotrexate and creatinine clearance are outcome determining factors in primary CNS lymphomas. Br J Cancer. 2004;90(2):353–8.PubMedCrossRef
6.
Zurück zum Zitat Tetef ML, Margolin KA, Doroshow JH, et al. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol. 2000;46(1):19–26.PubMedCrossRef Tetef ML, Margolin KA, Doroshow JH, et al. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol. 2000;46(1):19–26.PubMedCrossRef
7.
Zurück zum Zitat Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374(9700):1512–20.PubMedCrossRef Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374(9700):1512–20.PubMedCrossRef
8.
Zurück zum Zitat Ferreri AJ, Licata G, Foppoli M, et al. Clinical relevance of the dose of cytarabine in the upfront treatment of primary cns lymphomas with methotrexate-cytarabine combination. Oncologist. 2011;16(3):336–41.PubMedCrossRef Ferreri AJ, Licata G, Foppoli M, et al. Clinical relevance of the dose of cytarabine in the upfront treatment of primary cns lymphomas with methotrexate-cytarabine combination. Oncologist. 2011;16(3):336–41.PubMedCrossRef
9.
Zurück zum Zitat DeAngelis LM, Seiferheld W, Schold SC, et al. Radiation therapy oncology group study 93–10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group study 93–10. J Clin Oncol. 2002;20(24):4643–8.PubMedCrossRef DeAngelis LM, Seiferheld W, Schold SC, et al. Radiation therapy oncology group study 93–10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group study 93–10. J Clin Oncol. 2002;20(24):4643–8.PubMedCrossRef
10.
Zurück zum Zitat Nelson DF. Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neurooncol. 1999;43(3):241–7.PubMedCrossRef Nelson DF. Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neurooncol. 1999;43(3):241–7.PubMedCrossRef
11.
Zurück zum Zitat Ferreri AJ, Deangelis L, Illerhaus G, et al. Wholebrain radiotherapy in primary CNS lymphoma. Lancet Oncol. 2011;12(2):118–9.PubMedCrossRef Ferreri AJ, Deangelis L, Illerhaus G, et al. Wholebrain radiotherapy in primary CNS lymphoma. Lancet Oncol. 2011;12(2):118–9.PubMedCrossRef
12.
Zurück zum Zitat Jahnke K, Korfel A, O’Neill BP, et al. International study on low-grade primary central nervous system lymphoma. Ann Neurol. 2006;59(5):755–62.PubMedCrossRef Jahnke K, Korfel A, O’Neill BP, et al. International study on low-grade primary central nervous system lymphoma. Ann Neurol. 2006;59(5):755–62.PubMedCrossRef
13.
Zurück zum Zitat Ferreri AJ, Verona C, Politi L, et al. Consolidation radiotherapy in primary CNS lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy. Int J Radiat Oncol Biol Phys. 2011;80(1):169–75.PubMedCrossRef Ferreri AJ, Verona C, Politi L, et al. Consolidation radiotherapy in primary CNS lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy. Int J Radiat Oncol Biol Phys. 2011;80(1):169–75.PubMedCrossRef
14.
Zurück zum Zitat Reni M, Ferreri AJ, Guha-Thakurta N, et al. Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. Int J Radiat Oncol Biol Phys. 2001;51(2):419–25.PubMedCrossRef Reni M, Ferreri AJ, Guha-Thakurta N, et al. Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. Int J Radiat Oncol Biol Phys. 2001;51(2):419–25.PubMedCrossRef
15.
Zurück zum Zitat Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11(11):1036–47.PubMedCrossRef Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11(11):1036–47.PubMedCrossRef
16.
Zurück zum Zitat Cabanillas F. How important is whole brain radiotherapy for treatment of primary CNS lymphoma? Lancet Oncol. 2010;11(11):1011–2.PubMedCrossRef Cabanillas F. How important is whole brain radiotherapy for treatment of primary CNS lymphoma? Lancet Oncol. 2010;11(11):1011–2.PubMedCrossRef
17.
Zurück zum Zitat Reni M, Zaja F, Mason W, et al. Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer. 2007;96(6):864–7.PubMedCrossRef Reni M, Zaja F, Mason W, et al. Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer. 2007;96(6):864–7.PubMedCrossRef
18.
Zurück zum Zitat Omuro AM, Taillandier L, Chinot O, et al. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol. 2007;85(2):207–11.PubMedCrossRef Omuro AM, Taillandier L, Chinot O, et al. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol. 2007;85(2):207–11.PubMedCrossRef
19.
Zurück zum Zitat Fischer L, Thiel E, Klasen HA, et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol. 2006;17(7):1141–5.PubMedCrossRef Fischer L, Thiel E, Klasen HA, et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol. 2006;17(7):1141–5.PubMedCrossRef
20.
Zurück zum Zitat Ferreri AJ, Dell’Oro S, Foppoli M, et al. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology. 2006;66:1435–8.PubMedCrossRef Ferreri AJ, Dell’Oro S, Foppoli M, et al. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology. 2006;66:1435–8.PubMedCrossRef
21.
Zurück zum Zitat Batchelor TT, Lesser GJ, Grossman SA. Rituximab monotherapy for relapsed or refractory primary central nervous system lymphoma (abstract). J Clin Oncol. 2008;26(Suppl):2043 (Abstract). Batchelor TT, Lesser GJ, Grossman SA. Rituximab monotherapy for relapsed or refractory primary central nervous system lymphoma (abstract). J Clin Oncol. 2008;26(Suppl):2043 (Abstract).
22.
Zurück zum Zitat Maza S, Kiewe P, Munz DL, et al. First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (zevalin) in primary CNS lymphoma. Neuro Oncol. 2009;11(4):423–9.PubMedCrossRef Maza S, Kiewe P, Munz DL, et al. First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (zevalin) in primary CNS lymphoma. Neuro Oncol. 2009;11(4):423–9.PubMedCrossRef
23.
Zurück zum Zitat Ferreri AJ, Reni M, Pasini F, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology. 2002;58(10):1513–20.PubMedCrossRef Ferreri AJ, Reni M, Pasini F, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology. 2002;58(10):1513–20.PubMedCrossRef
24.
Zurück zum Zitat Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol. 2008;26:2512–8.PubMedCrossRef Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol. 2008;26:2512–8.PubMedCrossRef
25.
Zurück zum Zitat Colombat P, Lemevel A, Bertrand P, et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006;38:417–20.PubMedCrossRef Colombat P, Lemevel A, Bertrand P, et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006;38:417–20.PubMedCrossRef
26.
Zurück zum Zitat Illerhaus G, Muller F, Feuerhake F, et al. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica. 2008;93:147–8.PubMedCrossRef Illerhaus G, Muller F, Feuerhake F, et al. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica. 2008;93:147–8.PubMedCrossRef
27.
Zurück zum Zitat Abrey LE, Moskowitz CH, Mason WP, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003;21:4151–6.PubMedCrossRef Abrey LE, Moskowitz CH, Mason WP, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003;21:4151–6.PubMedCrossRef
28.
Zurück zum Zitat Ferreri AJ, Crocchiolo R, Assanelli A, et al. High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions. Leuk Lymphoma. 2008;49(11):2042–7.PubMedCrossRef Ferreri AJ, Crocchiolo R, Assanelli A, et al. High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions. Leuk Lymphoma. 2008;49(11):2042–7.PubMedCrossRef
Metadaten
Titel
Appraisal of recent knowledge in primary central nervous system lymphoma
verfasst von
Emerenziana Marturano, MD
Andrés J. M. Ferreri, MD
Publikationsdatum
01.12.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0055-7

Weitere Artikel der Ausgabe 4/2012

memo - Magazine of European Medical Oncology 4/2012 Zur Ausgabe